BR112014004515A2 - "compostos antibacterianos, seu uso, composição farmacêutica e combinação terapêutica que os compreende" - Google Patents

"compostos antibacterianos, seu uso, composição farmacêutica e combinação terapêutica que os compreende"

Info

Publication number
BR112014004515A2
BR112014004515A2 BR112014004515A BR112014004515A BR112014004515A2 BR 112014004515 A2 BR112014004515 A2 BR 112014004515A2 BR 112014004515 A BR112014004515 A BR 112014004515A BR 112014004515 A BR112014004515 A BR 112014004515A BR 112014004515 A2 BR112014004515 A2 BR 112014004515A2
Authority
BR
Brazil
Prior art keywords
gram
compounds
methods
pharmaceutical composition
antibacterial compounds
Prior art date
Application number
BR112014004515A
Other languages
English (en)
Inventor
I Gerasyuto Aleksey
Branstrom Arthur
Karp Gary
Chen Guangming
Qi Hongyan
Narasimhan Jana
Wang Jiashi
David Baird John
G Woll Matthew
Andrew Arnold Michael
Zhang Nanjing
Ginzburg Olya
Wesley Smith Sean
Peddi Srinivasa
Yang Tianle
Prasad Venkata Nagendra Josyula Vara
Zhang Xiaoyan
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47756844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014004515(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of BR112014004515A2 publication Critical patent/BR112014004515A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

abstract the present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant gram-negative and gram-positive pathogens. ____________________________________________________________________________ tradução do resumo resumo patente de invenção: "compostos antibacterianos e métodos para uso". a presente descrição se refere a compostos e formas e composições farmacêuticas dos mesmos e métodos para uso dos mesmos para tratar ou aliviar infecções bacterianas causadas por patógenos gram-negativos e gram-positivos do tipo selvagem e resistentes a múltiplos fármacos.
BR112014004515A 2011-08-29 2012-08-29 "compostos antibacterianos, seu uso, composição farmacêutica e combinação terapêutica que os compreende" BR112014004515A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161528599P 2011-08-29 2011-08-29
PCT/US2012/052922 WO2013033258A1 (en) 2011-08-29 2012-08-29 Antibacterial compounds and methods for use

Publications (1)

Publication Number Publication Date
BR112014004515A2 true BR112014004515A2 (pt) 2017-03-28

Family

ID=47756844

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004515A BR112014004515A2 (pt) 2011-08-29 2012-08-29 "compostos antibacterianos, seu uso, composição farmacêutica e combinação terapêutica que os compreende"

Country Status (14)

Country Link
US (1) US9409905B2 (pt)
EP (1) EP2750504A4 (pt)
JP (1) JP2014525453A (pt)
KR (1) KR20140097118A (pt)
CN (1) CN103889224B (pt)
AU (1) AU2012301953C1 (pt)
BR (1) BR112014004515A2 (pt)
CA (1) CA2846663A1 (pt)
CL (1) CL2014000469A1 (pt)
HK (1) HK1199693A1 (pt)
IL (1) IL231060A (pt)
MX (1) MX2014002298A (pt)
WO (1) WO2013033258A1 (pt)
ZA (1) ZA201402248B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525452A (ja) * 2011-08-29 2014-09-29 ピーティーシー セラピューティクス， インコーポレイテッド 抗菌化合物および使用方法
EP2970119B1 (en) * 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014157382A1 (ja) * 2013-03-29 2014-10-02 味の素株式会社 スフィンゴシンキナーゼ阻害剤
WO2016039939A1 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds
WO2016039937A1 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds
WO2016109706A1 (en) * 2014-12-31 2016-07-07 Ptc Therapeutics, Inc. Fused polycyclic 2-pyridinone antibacterial compounds
US11130740B2 (en) 2017-04-25 2021-09-28 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1H-indene analogs and methods using same
WO2018225828A1 (ja) * 2017-06-08 2018-12-13 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
CN107325080B (zh) * 2017-08-30 2020-05-12 延边大学 含三嗪或氨基胍结构的咔唑类衍生物的制备方法及其抗菌应用
GB2571950A (en) * 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
CN108659091B (zh) * 2018-05-24 2020-07-03 烟台大学 夫西地酸衍生物及其合成制备方法和应用
WO2020037155A1 (en) * 2018-08-16 2020-02-20 Recreo Pharmaceuticals Llc 1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indole derivative compounds and uses thereof
CN109329290A (zh) * 2018-10-11 2019-02-15 四川省兰月科技有限公司 防治猕猴桃、柑橘黄化病的农药组合物
CN109485601B (zh) * 2018-12-23 2020-06-30 沧州普瑞东方科技有限公司 2,6-二卤吡啶-3-羧酸的合成方法
CN111521706A (zh) * 2020-05-11 2020-08-11 苏州必宜生物科技有限公司 一种快速检测血浆中头孢克肟浓度的方法
WO2023127806A1 (ja) * 2021-12-28 2023-07-06 日本農薬株式会社 アリールテトラヒドロピリジン誘導体又はその塩類及び該化合物を含有する有害生物防除剤並びにその使用方法
CN115960031A (zh) * 2023-01-06 2023-04-14 暨南大学 一种四氢异吲哚酮类化合物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3948903A (en) * 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US3954734A (en) 1974-01-21 1976-05-04 Parke, Davis & Company Novel antibacterial amide compounds and process means for producing the same
JPS5643288A (en) 1979-09-18 1981-04-21 Meiji Seika Kaisha Ltd Cephalosporin derivative and its preparation
JPS5651488A (en) 1979-10-02 1981-05-09 Meiji Seika Kaisha Ltd Penicillin derivative and its preparation
DE3338846A1 (de) * 1982-10-29 1984-05-03 Toyama Chemical Co. Ltd., Tokyo Neue 4-oxo-1,4-dihydronicotinsaeurederivate und salze derselben, verfahren zu ihrer herstellung und antibakterielle mittel mit einem gehalt derselben
EP0308020A3 (en) * 1987-09-18 1990-12-05 Merck & Co. Inc. 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof
GB8809481D0 (en) 1988-04-21 1988-05-25 Smith Kline French Lab Chemical compounds
CA2081982A1 (en) * 1990-05-21 1991-11-22 Kenneth John Murray Phenol and pyridinol derivatives as pharmaceuticals
DE19639817A1 (de) * 1996-09-27 1998-04-02 Hoechst Ag Verwendung von 1-Hydroxy-2-pyridonen zur Behandlung von Hautinfektionen
CN1231161A (zh) 1998-07-07 1999-10-13 邱泽国 全自动多功能超声波洗碗机
JP2004536023A (ja) 2000-11-20 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー ａＰ２インヒビターとしてのピリドン誘導体
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CN101531631B (zh) * 2002-02-14 2011-09-28 法玛西雅公司 作为p38map激酶调节剂的取代吡啶酮类
DE60330126D1 (de) 2002-02-14 2009-12-31 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
JP2008531671A (ja) * 2005-03-04 2008-08-14 アストラゼネカ アクチボラグ 化合物
SI1879877T1 (sl) 2005-05-03 2013-02-28 Ranbaxy Laboratories Limited Protimikrobna sredstva
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
JP2014525452A (ja) * 2011-08-29 2014-09-29 ピーティーシー セラピューティクス， インコーポレイテッド 抗菌化合物および使用方法
MX2014002299A (es) * 2011-08-29 2014-07-22 Ptc Therapeutics Inc Compuestos antibacterianos y metodos para su uso.

Also Published As

Publication number Publication date
CN103889224B (zh) 2017-05-24
US9409905B2 (en) 2016-08-09
CA2846663A1 (en) 2013-03-07
KR20140097118A (ko) 2014-08-06
US20150038437A1 (en) 2015-02-05
CN103889224A (zh) 2014-06-25
EP2750504A1 (en) 2014-07-09
HK1199693A1 (en) 2015-07-17
MX2014002298A (es) 2014-07-22
CL2014000469A1 (es) 2014-11-14
NZ623063A (en) 2016-04-29
IL231060A (en) 2017-01-31
JP2014525453A (ja) 2014-09-29
WO2013033258A1 (en) 2013-03-07
IL231060A0 (en) 2014-03-31
AU2012301953B2 (en) 2016-05-12
ZA201402248B (en) 2016-06-29
AU2012301953C1 (en) 2016-11-03
EP2750504A4 (en) 2015-03-11
AU2012301953A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
BR112014004515A2 (pt) "compostos antibacterianos, seu uso, composição farmacêutica e combinação terapêutica que os compreende"
BR112014004832A2 (pt) compostos antibacterianos e métodos para uso
BR112014004704A2 (pt) compostos antibacterianos e métodos de uso
SV2016005274A (es) Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
GT201400111A (es) Triazolopiridinas sustituidas
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
BR112013032974A2 (pt) "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112014024279A8 (pt) Compostos heterobicíclicos como inibidores de beta-lactamase, composição farmacêutica, uso de um composto
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR122014013631B8 (pt) compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BR112014022214A2 (pt) fenólicos antibacterianos
BR112016006589A2 (pt) composição, e composição de vacina
CL2014001154A1 (es) Compuestos derivados antibioticos de 2-oxo-oxazolidin-3,5-diilo de formula i; composicion farmaceutica; uso para la prevencion o tratamiento de una infeccion bacteriana.
BR112015029367A8 (pt) combinação compreendendo oxazolidinonaquinolonas, seu uso, composição farmacêutica, e kit de partes
CO6650348A2 (es) Triazolopiridinas sustituidas
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
CL2013002313A1 (es) Compuestos macrólidos derivados de eritromicina sustituidos en posición c-4” con metil amino sustituido con actividad antibiótica; compuestos intermediarios; composición farmacéutica, uso en profilaxis o tratamiento de infecciones bacterianas resistentes a la eritromicina.
BR112017011980A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção bacteriana.
BR112017020796A2 (pt) compostos, composição farmacêutica e kit
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
CL2017001276A1 (es) Derivados de benzotiazol antibacterianos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.